{"nctId":"NCT00070941","briefTitle":"SAM-e for the Treatment of Depression in Patients With Parkinson's Disease","startDateStruct":{"date":"2003-07"},"conditions":["Parkinson's Disease","Depression"],"count":29,"armGroups":[{"label":"SAM-e","type":"EXPERIMENTAL","interventionNames":["Drug: SAM-e"]},{"label":"Escitalopram","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oral escitalopram"]},{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"SAM-e","otherNames":["1 Experimental"]},{"name":"oral escitalopram","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Idiopathic Parkinson's disease as indicated by the presence of at least two of the following signs: resting tremor, rigidity, bradykinesia, or postural reflex impairment\n* Stable anti-parkinson medication regimen, with no change in medications in the 4 weeks prior to study entry\n* No antidepressant or antipsychotic medications within 30 days prior to study entry\n* Agree not to start other pharmacotherapy, psychotherapy, or behavior therapy while participating in the trial\n* Acceptable methods of contraception\n* Ability to read and/or follow written and oral instructions presented in English\n* Sufficient cognitive ability (baseline Mini-Mental Status \\> 24) to provide informed consent\n\nExclusion Criteria\n\n* History of cardiac, hepatic, renal, hematologic, respiratory, endocrine, vascular, metabolic, or other systems abnormalities that are clinically relevant in the opinion of study officials\n* Certain abnormal laboratory values\n* Pregnant or breastfeeding\n* Use of an investigational drug within 3 months of study entry\n* Use of St. John's Wort or any other \"natural\" product known to have mood enhancing properties in the 30 days prior to study entry\n* Selegiline or other monoamine oxidase inhibitor within the 6 weeks prior to study entry\n* Regular usage of anti-anxiety medications or habitual use of sleep medications, although occasional use of certain hypnotics (temazepam, melatonin, or zolpidem) is allowed\n* Psychotherapy initiated in the 6 months prior to study entry\n* History of bipolar disorder, hypomania, mania, schizophrenia, or other psychotic disorder\n* Serious suicidal attempt in the 12 months prior to study entry or serious suicidal tendencies/potential\n* Use of dopamine receptor antagonist (metoclopramide, haloperidol)\n* Secondary Parkinsonian symptoms due to drugs (including dopamine receptor antagonists), metabolic disorders, cerebrovascular disease, encephalitis, or other degenerative diseases","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hamilton Depression Scale","description":"very severe, \\>23/29; severe, 19-22/29; moderate, 14-18/29; mild, 8-13/29; and no depression, 0-7/29 (Hamilton M., J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":"4.8"},{"groupId":"OG001","value":"17.5","spread":"5.4"},{"groupId":"OG002","value":"20.7","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"7.3"},{"groupId":"OG001","value":"5.3","spread":"3.3"},{"groupId":"OG002","value":"16.2","spread":"3.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["INSOMNIA","NAUSEA","CONSTIPATION","MOUTH DRY","ANOREXIA"]}}}